Clinical trials: Liver Diseases, Alcoholic
Non-alcoholic Fatty Liver Disease
Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
This study will evaluate changes in liver fat content following multiple oral doses of MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
- Trial name
- NCT01431521
- Testing
- MK-4074 200 mg, Pioglitazone hydrochloride 30 mg
- Volunteers
- 31 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 2, NAFLD
Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients
Patients with type 2 diabetes and non-alcoholic fatty liver disease will be enrolled. According to a parallel design, the participants will be randomized to a Portfolio diet or a monounsaturated fatty acid (MUFA)-rich diet (used…
- Trial name
- MEDEA (NCT03380416)
- Testing
- Portfolio Diet, MUFA Diet
- Where
- Italy
- Volunteers
- 49 people
- Sponsor
- Federico II University
Non-Alcoholic Fatty Liver Disease
Lysosomal Acid Lipase Activity in Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disease affecting a quarter of the world population. Pathological accumulation of fat, into the hepatocytes, is the first hit and is due to altered hepatic and…
- Trial name
- NAFLD LAL (NCT05419765)
- Testing
- Peripheral blood withdrawn
- Where
- Italy
- Volunteers
- 316 people
- Sponsor
- University of Roma La Sapienza
Obesity, NASH - Nonalcoholic Steatohepatitis
Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"
The NAFLD is the first cause of liver disease worldwide. The severe form of NAFLD, the NASH progresses to cirrhosis and is responsible of liver mortality.
- Trial name
- LLIFT (NCT04616664)
- Where
- 7 sites in France
- Volunteers
- 158 people
- Sponsor
- University Hospital, Lille
Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as evidenced by histopathological improvements in fibrosis in adult NASH subjects…
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
- Trial name
- ASCEND (NCT05402371)
- Testing
- Rencofilstat
- Where
- 41 sites in United States, France and 1 more
- Volunteers
- 120 people
- Sponsor
- Hepion Pharmaceuticals, Inc.
Nash
Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease
This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome.
- Trial name
- NCT01269320
- Testing
- Femarelle
- Where
- Israel
- Sponsor
- Hadassah Medical Organization
NAFLD, Type 2 Diabetes
Study Visceral Adipose Tissue and Liver Stifness in a Retrospective Cohort of Diabetes Mellitus Patients
Non Alcoholic Fatty Liver Disease (NAFLD) is an emergent disease worldwide, and soon the leading cause of hepatic transplant in the USA.
- Trial name
- NCT04493814
- Where
- France
- Volunteers
- 86 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Alcoholic Liver Disease
Gut Mycobiome Profile in Alcoholic Liver Disease.
The fecal mycobiome, which refers to the community of fungi that resides in the human gut, is an important component of the gut microbiome.
- Trial name
- NCT05793190
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Chuncheon Sacred Heart Hospital
Non-alcoholic Steatohepatitis, Hypertriglyceridemia
Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects
This is a multi-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in non-alcoholic steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) subjects…
- Conditions
- Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
- Trial name
- NCT02681055
- Testing
- MN-001
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- MediciNova
Non-Alcoholic Fatty Liver Disease, NAFLD
Economic Burden of NAFLD
To determine the economic burden of NAFLD (Non-Alcoholic-Fatty-Liver Disease) patients in Belgium, Flanders by means of a bottom-up approach.
- Trial name
- NCT05035043
- Testing
- Determination of the economic burden NAFLD patients
- Where
- Belgium
- Volunteers
- 73 people
- Sponsor
- Hasselt University
Self-Efficacy, Health Literacy
Health Literacy and Self-efficacy Expectations in Patients With Alcohol-related Liver Cirrhosis
The goal of this observational study is to quantify the health literacy and self-efficacy in people with alcohol-related liver cirrhosis.
- Conditions
- Self-Efficacy, Health Literacy, Liver Cirrhosis, ALD - Alcoholic Liver Disease
- Trial name
- GESA (NCT07169526)
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Hannover Medical School
Non-alcoholic Fatty Liver Disease
Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Liver Transplant Recipients
The purpose of this study is is to use non-invasive diagnostic tests, Fibroscan and a simple blood test, to diagnose NASH in patients who undergo liver transplantation.
- Trial name
- NCT03128918
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Type2 Diabetes, NAFLD
Whey or Casein - Liver Fat Reduction and Metabolic Improvement by Fast vs. Slow Proteins
High-protein diets have been recently demonstrated to effectively reduce insulin resistance, derangements of the lipid profile and liver fat content in subjects with moderately and severely impaired glucose metabolism and…
- Trial name
- MOCA (NCT04564391)
- Testing
- protein supplement
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
NAFLD, Obesity
Intermittent Fasting, Mediterranean Diet and NAFLD
This study aims to evaluate the effects of Intermittent Fasting (IF) 14/10 compared with the Low Glycemic Index Mediterranean Diet on NAFLD.
- Conditions
- NAFLD, Obesity, Intermittent Fasting, Mediterranean Diet
- Trial name
- RC2024-21 (NCT06615817)
- Testing
- Intermittent Fasting
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Non-Alcoholic Fatty Liver Disease
Fatty Liver Disease in Nordic Countries
A prospective cohort study, which aims to systematically evaluate biomarkers and potential targets in NAFLD and NASH.
- Trial name
- FLINC (NCT04340817)
- Testing
- Proteomics, Transcriptomics, Genomics
- Where
- Denmark
- Volunteers
- 634 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Hvidovre
Hepatic Cirrhosis, Liver Fibrosis
A Study of Experimental Medication BMS-986036 Given to Healthy Participants
This is a study of experimental medication BMS-986036 given to healthy participants.
- Conditions
- Hepatic Cirrhosis, Liver Fibrosis, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
- Trial name
- NCT03445208
- Testing
- BMS-986036
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Hepatitis, Alcoholic
Pentoxifylline for Acute Alcoholic Hepatitis (AAH)
The goal of this study is to demonstrate the effectiveness of pentoxifylline compared to placebo in AAH while studying putative mechanisms that are plausible and testable.
- Trial name
- NCT00205049
- Testing
- pentoxifylline
- Volunteers
- 4 people
- Sponsor
- University of Wisconsin, Madison
Non-Alcoholic Fatty Liver Disease, Liver Steatosis
Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18)
The goal of this clinical study is to compare the therapeutic effect of Dulaglutide and Empagliflozin in patients with Diabetes Mellitus type 2 and Non-Alcoholic Fatty Liver Disease.
- Trial name
- NAMELS-18 (NCT05946148)
- Testing
- Empagliflozin, Dulaglutide, Control Rx
- Where
- Greece
- Volunteers
- 78 people
- Sponsor
- National and Kapodistrian University of Athens
Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH)
Simultaneous Quantification of Liver Fat Content, Fatty Acid Composition, and Fibrosis Using Spin-lock MRI for Steatohepatitis Assessment
Non-alcoholic fatty liver disease is a major health problem worldwide. It includes simple steatosis and NASH which has inflammation in the liver, with or without fibrosis.
- Trial name
- NCT05384652
- Where
- Hong Kong
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
NAFLD (Nonalcoholic Fatty Liver Disease), Polycystic Ovarian Syndrome (PCOS)
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
To study the prevalence, non-invasive diagnostics and evolution of non-alcoholic-fatty-liver-disease (NAFLD) in patients with polycystic ovary syndrome (PCOS)
- Trial name
- P-CORIGA (NCT07146815)
- Testing
- FibroScan, MRI PDFF
- Where
- Belgium
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Ziekenhuis Oost-Limburg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.